Investor Presentaiton
Investor presentation
Full year 2018
Slide 40
Growth opportunities supported by strong global presence
in both sales and manufacturing
Employees in sales regions¹
North America Operations:
Region AAMEO:
Region China:
Region Europe:
Region Japan & Korea:
Region Latin America:
Global manufacturing setup
West Lebanon, NH, USA
(~188 employees)
Biopharmaceutical
API production
Denmark (~9,000 employees)
Diabetes and biopharmaceutical
API production
Filling and packaging
Moulding and assembly
Tablet production
Kaluga, Russia
(~266 employees)
Filling
Assembly
Packaging
~4,100
~4,700
~3,300
~2,900
Clayton, NC, USA
(~1,186 employees)
~900
~970
Total non-HQ/manufacturing employees: ~18,000¹
Koriyama, Japan
(~70 employees)
Packaging
Diabetes API production
Filling
Assembly
Packaging of above
Chartres, France
(~1,140 employees)
Filling
Assembly
Packaging
Tianjin, China
(~1,045 employees)
Filling
Assembly
Packaging
Montes Claros, Brazil
(~980 employees)
Filling
Assembly
Packaging
Tizi Ouzou, Algeria
(~240 employees)
Tablet production
1 Employees represent full-time equivalents in Novo Nordisk's sales regions (excludes all other employees in headquarter, research sites and manufacturing sites) as of December 2018
AAMEO: Africa, Asia, the Middle-East and Oceania.
changing
diabetes
novo nordiskView entire presentation